1738 related articles for article (PubMed ID: 21301376)
1. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
2. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
3. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
4. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
[TBL] [Abstract][Full Text] [Related]
6. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT.
Aide N; Cappele O; Bottet P; Bensadoun H; Regeasse A; Comoz F; Sobrio F; Bouvard G; Agostini D
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1236-45. PubMed ID: 12845486
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies.
Nakhoda Z; Torigian DA; Saboury B; Hofheinz F; Alavi A
Hell J Nucl Med; 2013; 16(1):19-24. PubMed ID: 23529389
[TBL] [Abstract][Full Text] [Related]
8. F-18 FDG PET in detecting renal cell carcinoma.
Ak I; Can C
Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.
Kang DE; White RL; Zuger JH; Sasser HC; Teigland CM
J Urol; 2004 May; 171(5):1806-9. PubMed ID: 15076281
[TBL] [Abstract][Full Text] [Related]
10. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.
Takahashi M; Kume H; Koyama K; Nakagawa T; Fujimura T; Morikawa T; Fukayama M; Homma Y; Ohtomo K; Momose T
Clin Nucl Med; 2015 Dec; 40(12):936-40. PubMed ID: 26164183
[TBL] [Abstract][Full Text] [Related]
11. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
12. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
13. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
14. Role of FDG PET-CT in recurrent renal cell carcinoma.
Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A
Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166
[TBL] [Abstract][Full Text] [Related]
15. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
[TBL] [Abstract][Full Text] [Related]
16. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses.
Kumar R; Chauhan A; Lakhani P; Xiu Y; Zhuang H; Alavi A
Mol Imaging Biol; 2005; 7(6):431-9. PubMed ID: 16307216
[TBL] [Abstract][Full Text] [Related]
17. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
[TBL] [Abstract][Full Text] [Related]
18. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
19. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
20. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
